Bayer AG BAYNN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bayer Promotes Christoph Koenen to Chief Medical Officer
-
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
-
Bayer Gets FDA Accelerated Approval for Lung Cancer Treatment
-
Missouri Court Grants Delay for Bayer's Roundup Settlement Hearing
-
Bayer CEO Rules out Group Breakup for Now — Update
-
Bayer Swings to Net Profit on Smaller Litigation Charges
-
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
-
German DAX On Track for First Record Since January
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 982.42M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 11.33
- Price/Sales
- 1.03
- Dividend Yield (Trailing)
- 0.22%
- Dividend Yield (Forward)
- 0.22%
- Dividend Payment Schedule
- Apr
- Total Yield
- 0.26%
Company Profile
Bayer is a German healthcare and agriculture conglomerate. Healthcare accounts for close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total sales). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, a segment that was expanded through its 2018 acquisition of Monsanto.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 87,830
- Website
- https://www.bayer.com
Competitors
Valuation
|
Metric
|
BAYNN
|
BASFY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.33 | 25.71 | 9.22 |
Price/Book Value | 1.66 | 1.16 | 1.88 |
Price/Sales | 1.03 | 0.69 | 2.53 |
Price/Cash Flow | 32.25 | 7.83 | 10.46 |
Price/Earnings
BAYNN
BASFY
PFE
Financial Strength
|
Metric
|
BAYNN
|
BASFY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.67 | 1.19 | 0.85 |
Current Ratio | 1.04 | 1.85 | 1.27 |
Interest Coverage | 0.27 | 3.59 | 2.36 |
Quick Ratio
BAYNN
BASFY
PFE
Profitability
|
Metric
|
BAYNN
|
BASFY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 4.50% | 0.97% | 8.46% |
Return on Equity (Normalized) | 16.50% | 2.27% | 19.70% |
Return on Invested Capital (Normalized) | 9.34% | 1.92% | 12.66% |
Return on Assets
BAYNN
BASFY
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|>?YGk&N | LOCK|HG | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|cNvfB# | LOCK|hqk | $623B | |||
| AbbVie Inc
ABBV
| LOCK|#kNQd& | LOCK|$<w | $459B | |||
| Merck & Co Inc
MRK
| LOCK|JKdL?b! | LOCK|HC | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|hp!tTL> | LOCK|&^V | $334B | |||
| Novartis AG ADR
NVS
| LOCK|N<^ywq^Y | LOCK|^# | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|?Q>qKkn@ | LOCK|dC | $252B | |||
| Amgen Inc
AMGN
| LOCK|#@&l&y# | LOCK|YhS | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|yfTR$>B | LOCK|<^ | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|RjRN#% | LOCK|R#? | $167B |
United States